1 xt] The recent finding that the FDA-approved
antiobesity agent orlistat (tetrahydrolipstatin, Xenical
2 Preliminary evidence suggests that the
antiobesity agent sibutramine is effective in the treatm
3 814580 (compound 10) as a highly efficacious
antiobesity agent with a relatively clean in vitro and i
4 6 would therefore have great potential as an
antiobesity agent.
5 a) are widely considered to offer utility as
antiobesity agents by lowering the set-point for hunger
6 ty profile to support clinical evaluation as
antiobesity agents has been a challenge.
7 Successful development of
antiobesity agents requires detailed knowledge of neural
8 heterodimer, with implications for potential
antiobesity agents that target centrally coexpressed Y1
9 t Y5 antagonists for evaluation as potential
antiobesity agents, a pharmacophore model for the human
10 a new class of dual-acting hypolipidemic and
antiobesity agents.
11 one-containing, selective 5-HT2C agonists as
antiobesity agents.
12 hrelin are unlikely to have broad utility as
antiobesity agents.
13 antagonists are currently being developed as
antiobesity and antidepressant drugs.
14 Because currently available
antiobesity and antidiabetic drugs have limited efficacy
15 Because resulting beige/brite cells exhibit
antiobesity and antidiabetic effects, nitrate may be an
16 ilities for future development of successful
antiobesity and antidiabetic therapies.
17 These results identify Rb1 as an
antiobesity and antihyperglycemic agent.
18 antimicrobial, antidiabetic, antioxidative,
antiobesity and antihypertensive effects.
19 an inhibition that appears to be due to the "
antiobesity,"
antihypertriglyceridemic, and antiinflamma
20 ors that show biased agonism and potentially
antiobesity behavior via a new mechanism.
21 alinolamide (6) were investigated in mice as
antiobesity compounds.
22 (CB1) have been demonstrated to be anorectic
antiobesity drug candidates.
23 ights this circuit as a promising target for
antiobesity drug development.
24 nsferases; these may provide new targets for
antiobesity drug therapy.
25 Orlistat, an
antiobesity drug, is cytostatic and cytotoxic to tumor c
26 Unless effective
antiobesity drugs are developed, the effect of obesity o
27 In this review, we will discuss the
antiobesity drugs with Food and Drug Administration appr
28 h for 5-HT2CR allosteric modulators as safer
antiobesity drugs, a chemical library from Vivia Biotech
29 been the target of potential anxiolytics and
antiobesity drugs, and its positive allosteric modulator
30 d with the stringent safety requirements for
antiobesity drugs, highlight the importance of incorpora
31 Despite the recent failures of a number of
antiobesity drugs, the pharmacotherapy of obesity is pro
32 ay be a valuable target for developing novel
antiobesity drugs.
33 g a new chemical entity for the discovery of
antiobesity drugs.
34 ol over fat intake and might be a target for
antiobesity drugs.
35 therefore have potential for development as
antiobesity drugs.
36 eptor antagonists with the aim of developing
antiobesity drugs.
37 s of Y4 receptors and as a lead compound for
antiobesity drugs.
38 This
antiobesity effect is attributed to an increase in the t
39 suggest that in ob/ob mice, the antidiabetic
antiobesity effect of leptin could be the result of a pr
40 ed risk of obesity but the mechanism for the
antiobesity effect of standing is unknown.
41 n-3 long-chain PUFAs (LC-PUFAs) may exert an
antiobesity effect.
42 Remarkably, the vast majority of leptin's
antiobesity effects are mediated by GABAergic neurons; g
43 The
antiobesity effects of DualAG require activation of both
44 The
antiobesity effects of ER-beta ligand were not observed
45 The recent publications of anorectic and
antiobesity effects of the first two selective MCH1-R an
46 Hypolipidemic and
antiobesity effects of the newly synthesized indole-base
47 robably mediates, at least in part, leptin's
antiobesity effects.
48 invalidates rodent models for assessing the
antiobesity efficacy of 14G: and 14H: .
49 We compared the effects of targeting
antiobesity interventions at the most connected individu
50 Proposed
antiobesity mechanisms of CLA include regulation of (a)
51 iasthma medication albuterol sulfate and the
antiobesity medications orlistat, phentermine hydrochlor
52 The feasibility of performing any primary
antiobesity operation safely laparoscopically was convin
53 ptamine, 5-HT) efficacy has been a target of
antiobesity pharmacotherapies.
54 ile synthetic agonists activating BRS-3 show
antiobesity profiles by inhibiting food intake and incre
55 This review examines whether CLA's
antiobesity properties are due to inflammatory signaling
56 ympathetic nervous system in mediating CLA's
antiobesity properties.
57 Both systems are exploited clinically as
antiobesity strategies.
58 These results identify KE as a potential
antiobesity supplement.
59 However,
antiobesity surgery entails very much more than techniqu
60 were most types of gastrointestinal surgery,
antiobesity surgery was dominated by the development of
61 -up, and devising strategies for reoperative
antiobesity surgery.
62 ising the possibility of using Syt4 as a new
antiobesity target.
63 GAT as a potential point of intervention for
antiobesity therapies.
64 Here, we report an
antiobesity therapy based on targeted induction of apopt
65 Aldh1 is a potential target for sex-specific
antiobesity therapy.
66 AT) because of its potential utilization for
antiobesity therapy.
67 ocytes and may constitute a novel target for
antiobesity therapy.
68 ase the effectiveness of MC4R agonists as an
antiobesity treatment.
69 us, this combination therapy may be a viable
antiobesity treatment.